1.Research Advances in Endocrine Therapy for Hormone Receptor-Positive/HER2-Negative Early Breast Cancer
Wenqin HUANG ; Yalong YANG ; Xinhong WU ; LAMBERTINI MATTEO ; Hongmei ZHENG
Cancer Research on Prevention and Treatment 2026;53(3):169-175
Hormone receptor (HR)-positive/HER2-negative early breast cancer is the most common subtype of breast cancer, and endocrine therapy serves as the cornerstone of adjuvant treatment. In recent years, with the publication of key clinical trials such as SOFT, TEXT, and monarchE, and breakthroughs in novel agents studies like lidERA, the endocrine therapy strategy for HR-positive/HER2-negative early breast cancer has evolved toward increased precision and intensity. This article systematically reviews the latest advances in endocrine therapy, focusing on the consolidation of ovarian function suppression as a standard for high-risk premenopausal patients with updated follow-up evidence, the benefit-risk assessment of extended endocrine therapy, and the current application and interdrug differences of CDK4/6 inhibitors in the adjuvant setting. This manuscript also addresses existing challenges, including optimizing treatment-related quality of life and precisely identifying beneficiary populations, and briefly introduces the clinical trial progress of novel agents, such as oral selective estrogen receptor degraders. Furthermore, it outlines evidence-based strategies for ovarian protection during chemotherapy and fertility preservation for young patients. This review aims to provide clinicians with a comprehensive perspective, balancing the pursuit of maximal efficacy with patients′ long-term quality of life and individualized needs.
2.Huaier Enhances Efficacy of Oxaliplatin in Treatment of Gastric Cancer by Improving Gut Microbiota
Shenglian ZHANG ; Zhimin DU ; Yi GONG ; Meiqi LAN ; Ping LIU ; Yajun XIONG ; Yanli GONG ; Xiaoyong SONG ; Junli LI ; Ruizhi WANG ; Yuting GAO ; Huanhu ZHANG ; Xinli SHI
Cancer Research on Prevention and Treatment 2026;53(3):176-186
Objective To elucidate the changes in the gut microbiota and molecular mechanism of huaier in
3.Effect of LncRNA OIP5-AS1 in Breast Cancer Cells on Macrophage Polarization and Feedback Regulation of Polarized Macrophages on Breast Cancer Cells
Enshuai YANG ; Zhe DONG ; Xinyue CHANG ; Ziyang XIAO ; Yang LIU ; Sufen GUO
Cancer Research on Prevention and Treatment 2026;53(3):187-193
Objective To explore the mechanism by which breast cancer-derived LncRNA OIP5-AS1 regulates the migration, invasion, and epithelial-mesenchymal transition of breast cancer cells through the M2 polarization of tumor-associated macrophages (TAM). Methods MDA-MB-231 cells were divided into the control group (blank control), the NC group (transfected with NC siRNA), and the si-OIP5 group (transfected with LncRNA OIP5-AS1 siRNA). The mRNA expression levels of LncRNAs OIP5-AS1, IL-4, and IL-13 were detected by RT-qPCR. The protein expression levels of IL-4 and IL-13 in the culture supernatant were detected by ELISA. The culture supernatant from the control group was added to RPMI
4.CEACAM6 Expression is Associated with Immune Infiltration and Poor Prognosis in Esophageal Squamous Cell Carcinoma
Jiahui LI ; Enwei XU ; Wei CUI ; Yuanyuan ZHAO ; Keqing KANG ; Peng BU ; Guohai ZHAO ; Yang ZHOU
Cancer Research on Prevention and Treatment 2026;53(3):194-202
Objective To investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in esophageal squamous cell carcinoma (ESCC) and analyze its correlation with immune cell infiltration and patient prognosis. Methods Three ESCC datasets (GSE161533, GSE26886, and GSE23400) from the GEO database were analyzed to identify differentially expressed genes. CEACAM6 was identified as a key gene through survival analysis. Its expression, prognostic value, and relationship with immune cell infiltration were further explored using databases, such as TIMER. Tissue samples were collected from 162 patients with ESCC. Immunohistochemistry was performed to detect the expression of CEACAM6, immune cell markers (CD4, CD8, CD20, and CD56), and immune checkpoint molecules (HHLA2 and CD40LG). Correlations between CEACAM6 expression and clinicopathological features, immune cell infiltration, and immune checkpoints were analyzed. Results Bioinformatic analysis and clinical sample validation confirmed that CEACAM6 expression was significantly upregulated in ESCC tissues compared with adjacent nontumor tissues (P<0.05). High CEACAM6 expression was closely associated with advanced clinical stage (AJCC Ⅲ-Ⅳ), high T stage (T3-T4), lymph node metastasis, nonulcerative type, and poor prognosis. Furthermore, CEACAM6 expression levels were positively correlated with the infiltration density of CD8+ T cells, CD4+ T cells, and CD20+ B cells within the tumor microenvironment and with the expression of the immune checkpoint molecules HHLA2 and CD40LG (all P<0.05). Conclusion CEACAM6 serves as an independent poor prognostic factor for ESCC. Its high expression is implicated in the modulation of the tumor immune microenvironment by correlating with specific immune cell infiltration and immune checkpoint molecules, suggesting its potential as a novel prognostic biomarker and immunotherapeutic target for ESCC.
5.Cancer Incidence and Mortality in Ya'an City in 2022 and Trends from 2013 to 2022
Qingxia LIU ; Ying TANG ; Shiyan YAN ; Ruyue ZHOU
Cancer Research on Prevention and Treatment 2026;53(3):203-210
Objective To analyze the incidence and mortality of cancer in Ya'an City in 2022 and its trends from 2013 to 2022. Methods The crude and age-standardized cancer incidence and mortality rates (based on the Chinese standard population) were calculated by gender and age group from the Ya'an City registry data for 2022, and their trends from 2013 to 2022 were assessed using Joinpoint regression analysis. Results In 2022, the crude incidence rate of cancer in Ya'an City was 317.19/105, and the age-standardized incidence rate was 178.45/105. The crude mortality rate of cancer in Ya'an City was 185.10/105, and the age-standardized mortality rate was 85.22/105. The top three cancer types with the highest incidence were lung cancer, colorectal cancer, and female breast cancer, and those with the highest mortality were lung cancer, colorectal cancer, and liver cancer. From 2013 to 2022, the overall age-standardized incidence rate of cancer was relatively stable but showed a downward trend in males (P<0.05) and an upward trend in females (P<0.05). The overall age-standardized mortality rate exhibited a downward trend (P<0.05). The age-standardized incidence rate of thyroid cancer, prostate cancer, and lung cancer showed an upward trend (P<0.05), whereas those of liver cancer, gastric cancer, and esophageal cancer showed a downward trend (P<0.05). The age-standardized mortality rate of gastric cancer, female breast cancer, liver cancer, and esophageal cancer showed a downward trend (P<0.05). Conclusion The burden of cancer remains severe in Ya'an City. Targeted interventions should be implemented for lung cancer, colorectal cancer, female breast cancer, liver cancer, thyroid cancer, prostate cancer, and other common cancers to effectively control the cancer burden.
6.Research Progress on Treatment of Liver Cancer with Mechanistic Insights into Herbal Medicine: Focus on NF-κB Signaling Pathway
Cancer Research on Prevention and Treatment 2026;53(3):211-218
Liver cancer ranks among malignancies with high global incidence and mortality rates, presenting significant therapeutic challenges. The NF-κB signaling pathway plays a pivotal role in pathogenesis, progression, and treatment of liver cancer, where its aberrant activation is intricately linked to tumor cell proliferation and the dysregulation of apoptosis. In recent years, targeting the inhibition of this pathway has become an important research direction in the treatment of liver cancer. Traditional Chinese medicine (TCM), characterized by multicomponent nature and multitarget effects, exhibits unique advantages in the management of liver cancer. In this article, the regulatory mechanisms of the NF-κB signaling pathway in liver cancer are systematically reviewed, and the research progress on how TCM exerts antitumor effects by inhibiting this pathway and inducing apoptosis in liver cancer cells is summarized. This work provides a theoretical basis and new insights for the study of single compounds and compound formulations of TCM against liver cancer.
7.Research Progress on Role and Mechanism of CKIP-1 in Tumor Immune Microenvironment
Cancer Research on Prevention and Treatment 2026;53(3):219-225
Casein kinase 2-interacting protein-1 (CKIP-1) is a multifunctional scaffold protein with a pleckstrin homology domain. Its dynamic subcellular localization enables dual roles in tumor progression, “promoting” or “suppressing” malignancy by regulating immune metabolism and signaling networks within the tumor immune microenvironment (TIME). This review synthesizes current knowledge on CKIP-1’s structural characteristics and TIME regulatory mechanisms. We highlight that CKIP-1 inhibits macrophage M2 polarization, antagonizes Smurf1-mediated oncoprotein ubiquitination, and modulates key pathways, including TGF-β and PI3K/AKT. Targeting CKIP-1 enhances the efficacy of immune checkpoint inhibitors and CAR-T therapy, but clinical translation faces challenges, such as unclear tissue-specific mechanisms and combination toxicity. This review aims to synthesize the regulatory functions of CKIP-1 in the tumor immune microenvironment, thereby offering a theoretical basis for precision immunotherapy targeting CKIP-1 and further analyzing its dynamic mechanisms to advance clinical applications.
8.Research Progress on Predictive Value of Inflammatory and Nutritional Indicators for Prognosis of Nasopharyngeal Carcinoma in the Era of Immunotherapy
Minglei CAI ; Ying LU ; Yajuan ZHOU
Cancer Research on Prevention and Treatment 2026;53(3):226-232
Nasopharyngeal carcinoma (NPC) is endemic to southern China. Currently, its treatment and prognosis reply primarily on the TNM staging system and EBV-DNA testing; however, these parameters have limitations in fully capturing the tumor’s biological heterogeneity and the host's immunonutritional status. In recent years, systemic inflammatory and nutritional indices, such as the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), prognostic nutritional index (PNI), and skeletal muscle index (SMI), have proven effective for assessing systemic inflammation and nutritional status. Accumulating evidence has demonstrated that these indicators are closely associated with treatment response, progression-free survival (PFS), and overall survival (OS) in NPC patients, and also show promise in predicting the efficacy of immune checkpoint inhibitors. This review aims to systematically elaborate on the prognostic value of these inflammatory and nutritional indicators in the context of NPC immunotherapy, to inform the development of individualized precision treatment strategies.
9.A Case of Autologous Reconstruction with TRAM Flap Combined with Contralateral Reduction in Lactational Patient with Breast Cancer and Macromastia
Weifang ZHANG ; Yueyao SUN ; Yanjun LIU ; Yifang WANG ; Xin CHEN ; Jie ZHANG ; Mengyang AN ; Bo LIU ; Fangjian SHANG
Cancer Research on Prevention and Treatment 2026;53(3):233-236
10.Impact of Nutritional Support on Antitumor Efficacy in the Era of Immunotherapy
Xiaojun QIAN ; Ling LU ; Xuecheng HU ; Shiwei LI ; Wenjun GAO ; Li PAN ; Yubei SUN ; Suyi LI
Cancer Research on Prevention and Treatment 2026;53(2):89-95
Despite breakthroughs in immunotherapy for solid tumors, significant variations in treatment efficacy persist. Up to 80% of cancer patients suffer from malnutrition, which leads to: lymphoid atrophy and reduced T-cell reserves; deficiency of substrates required for T-cell activation and expansion; concurrent inflammation hindering T-cell infiltration into tumors; and cachexia accelerating PD-1 antibody clearance. Clinical studies confirm that severe malnutrition significantly impairs immune responses and increases the risk of treatment toxicity. Therefore, implementing standardized nutritional therapy is crucial for optimizing the reserve, activation, expansion, and infiltration capacity of immune cells, thereby providing a sound immune system foundation for immunotherapy. Immunonutrition therapy, by enhancing immunonutrients such as arginine, omega-3 polyunsaturated fatty acids, and nucleotides, reduces the secretion of pro-inflammatory mediators and promotes T-cell activation and proliferation. This enhances anti-tumor immune responses, prolongs survival, and advances cancer treatment towards multimodal combination and precision approaches.

Result Analysis
Print
Save
E-mail